comparemela.com

Page 14 - Resistant News Today : Breaking News, Live Updates & Top Stories | Vimarsana

atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression

NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) atai Life Sciences (NASDAQ: ATAI) ("atai" or "the Company"), a clinical-stage biopharmaceutical company focused on mental health, announced that,

New yorkUnited statesAllan malievskyExchange commissionPerception neuroscience incCompany contactLife sciencesSecurities exchangeOtsuka pharmaceutical co ltdPerception neuroscienceDepression rating scaleFlorian brandStudy designClinician administered dissociative states scaleModified observerSedation scale

KBP Biosciences: Ocedurenone (KBP-5074) Featured at ASN Kidney Week: Ocedurenone is a Potential New Treatment Option for Patients with Uncontrolled or Resistant Hypertension and Advanced CKD

Hepatic Impairment and Drug-Drug Interaction Study Results Presented PRINCETON, N.J., Jan. 6, 2023 /PRNewswire/ KBP Biosciences PTE. Ltd. ("KBP Biosciences" or the "Company"), a clinical-stage

United statesSan antonioKostenloser wertpapierhandelJames mccabeUniversity of chicago medical centerAmerican heart association comprehensive hypertension centerAmerican heart association scientific sessionsRenal associatesUniversity of michiganHepatic impairmentDrug interaction study resultsPablo pergolaMineralocorticoid receptor blockerUncontrolled hypertensionAmerican heart associationComprehensive hypertension center

S2Medical AB: Positive outcome when S2Medicals antimicrobial peptides were tested against the multi resistant bacteria that by WHO have been defined as a global health threat

LINKÖPING, Sweden, Jan. 2, 2023 /PRNewswire/ Scientists from the HeAliX-project which the Company is a part of have evaluated the antimicrobial effect from the peptide technology that the

Petter sivlUniversity of technologyAbuse regulation

Merck & Co , Inc : LYNPARZA (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer

First PARP inhibitor and new hormonal agent combination approved for these patients in Europe AstraZeneca and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced

United statesJulie cunninghamPeter dannenbaumDamini chokshiMichael mcardleEuropean commissionStatement of merck co incProstate cancer working groupMerck co incExchange commissionCommittee for medicinal products humanEuropean unionMedicinal productsHuman useAcute myeloid leukemiaThromboembolic events

Price reduction for expanding access to highly effective MDR tuberculosis treatment

Pretomanid, used within the BPaL and BPaLM regimens, is already being piloted and implemented in operational research programmes run by government agencies and civil society organisations

Pretomanid paTb allianceNational tuberculosis elimination programWorld health organisationDrug controller general

vimarsana © 2020. All Rights Reserved.